Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.
Research Interests

Papers共 191 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Short-term Treatment of CIDP with Efgartigimod: a Case Series in China
Chong Sun, Jianian Hu,Yanyin Zhao, Yongsheng Zheng, Quanhua Meng,Sushan Luo,Kai Qiao,Jian Sun,Jiahong Lu,Jie Lin,Chongbo Zhao
Frontiers in immunology (2025): 1533167-1533167
Cited0Views0WOSBibtex
0
0
Serum Cystatin C As a Potential Biomarker for Generalized Acetylcholine Receptor Antibody-Positive Myasthenia Gravis
Dingxian He, Huahua Zhong, Lei Jin, Ran Chen, Zongtai Wu,Rui Zhao, Xiao Huan,Chong Yan,Jie Song,Jianying Xi,Chongbo Zhao, Shanfeng Zhu,Sushan Luo
Frontiers in immunology (2025): 1578359-1578359
Cited0Views0WOSBibtex
0
0
Response of Refractory Residual Ocular Symptoms to Efgartigimod in Generalized Myasthenia Gravis: A Real-World Case Series
Dingxian He, Yufan Zhou, Yexin Zhang, Jialong Zhang,Chong Yan,Sushan Luo,Chongbo Zhao,Jianying Xi
Journal of Neuroimmunology (2025): 578558
Cited0Views0WOSBibtex
0
0
Efgartigimod for Induction and Maintenance Therapy in Muscle-Specific Kinase Myasthenia Gravis
Yufan Zhou,Qian Zhou,Yaoxian Yue,Sushan Luo,Jie Song,Chong Yan, Dingxian He, Jialong Zhang,Wenhua Zhu,Chongbo Zhao,Huan Yang,Qinzhou Wang,Jianying Xi
Therapeutic advances in neurological disorders (2025): 17562864251326778-17562864251326778
Cited0Views0WOSBibtex
0
0
Load More
Author Statistics

#Papers: 191

#Citation: 1500

H-Index: 22

G-Index: 31

Sociability: 7

Diversity: 3

Activity: 51

  • 合作者
  • 学生
  • 导师
No result temporarily, you can search similar Scholar with the same research interest
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn